{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:22:18Z","timestamp":1792592538737,"version":"4.5.0"},"reference-count":52,"publisher":"American Chemical Society (ACS)","issue":"29","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020084","name":"Guangzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["2025A03J3517"],"award-info":[{"award-number":["2025A03J3517"]}],"id":[{"id":"10.13039\/501100020084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82305177"],"award-info":[{"award-number":["82305177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Traditional Chinese Medicine","award":["20222A011007"],"award-info":[{"award-number":["20222A011007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent advances in immune checkpoint inhibitors (ICIs), particularly those targeting PD-1\/PD-L1, have transformed cancer treatment. However, their efficacy is often hampered by the immunosuppressive tumor microenvironment (TME). Here, we developed a cantharidin-loaded nanomedicine (CA@TPGS-AmP), composed of D-\u03b1-tocopheryl polyethylene glycol succinate (TPGS) and naturally derived amphiphilic peptides (AmP), designed to enhance PD-1 blockade via induction of immunogenic cell death (ICD). In vitro, CA@TPGS-AmP markedly improved the solubility of cantharidin and exhibited superior penetration in 3D tumor spheroids. It effectively triggered key ICD events, including calreticulin (CRT) surface exposure, ATP release, and HMGB1 translocation, thereby promoting dendritic cell (DC) maturation. In vivo, CA@TPGS-AmP significantly augmented the antitumor efficacy of PD-1 therapy in 4T1 orthotopic breast cancer and LLC lung cancer models. Mechanistically, the combination therapy remodeled the TME into an immunostimulatory state by increasing CD8+ T cell infiltration and activation, leading to enhanced tumor suppression compared to monotherapies. These findings support CA@TPGS-AmP as a promising adjunct to PD-1 blockade and highlight the potential of natural product-based nanomedicine in advancing cancer immunotherapy.<\/jats:p>","DOI":"10.1021\/acsami.5c05498","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T11:06:41Z","timestamp":1751972801000},"page":"41571-41585","source":"Crossref","is-referenced-by-count":12,"title":["Cantharidin-Loaded\nNanomedicine Modified with Amphiphilic\nPeptides Induce Immunogenic Cell Death to Enhance PD-1 Blockade"],"prefix":"10.1021","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4217-6210","authenticated-orcid":true,"given":"Yang","family":"Tang","sequence":"first","affiliation":[{"name":"Guangzhou Medical University , , ,","place":["Guangzhou, China, 510000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Jiang","sequence":"additional","affiliation":[{"name":"Guangzhou University of Chinese Medicine , ,","place":["Guangzhou, China, 510000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongli","family":"Chen","sequence":"additional","affiliation":[{"name":"Chinese Academy of Sciences , , ,","place":["Zhongshan, China, 528437"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Wu","sequence":"additional","affiliation":[{"name":"Guangzhou University of Chinese Medicine , ,","place":["Guangzhou, China, 510000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichang","family":"Luo","sequence":"additional","affiliation":[{"name":"Guangzhou Medical University , , ,","place":["Guangzhou, China, 510000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Huang","sequence":"additional","affiliation":[{"name":"Guangzhou Medical University , , ,","place":["Guangzhou, China, 510000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofang","family":"Yu","sequence":"additional","affiliation":[{"name":"Guangzhou Medical University , , ,","place":["Guangzhou, China, 510000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Shao","sequence":"additional","affiliation":[{"name":"Guangzhou Medical University , , ,","place":["Guangzhou, China, 510000"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"5","key":"2026072521082602900_cit1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant\nChemoimmunotherapy for NSCLC: A Systematic\nReview and Meta-Analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA oncology"},{"issue":"10","key":"2026072521082602900_cit2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101206","article-title":"Ablation\nof ERO1A induces lethal endoplasmic reticulum stress responses\nand immunogenic cell death to activate anti-tumor immunity","volume":"4","author":"Liu","year":"2023","journal-title":"Cell reports. Medicine"},{"issue":"1","key":"2026072521082602900_cit3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1021\/acsami.3c14068","article-title":"Endoplasmic\nReticulum-Targeting AIE Photosensitizers\nto Boost Immunogenic Cell Death for Immunotherapy of Bladder Carcinoma","volume":"16","author":"Miao","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2026072521082602900_cit4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cytogfr.2024.08.001","article-title":"Targeting\nPD-1\/PD-L1 in tumor immunotherapy:\nMechanisms and interactions with host growth regulatory pathways","volume":"79","author":"Shen","year":"2024","journal-title":"Cytokine & growth factor reviews"},{"issue":"4","key":"2026072521082602900_cit5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade\nof immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nature reviews. Cancer"},{"issue":"9","key":"2026072521082602900_cit6","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen\npresentation in cancer -\nmechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nature reviews. Clinical oncology"},{"key":"2026072521082602900_cit7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.semcancer.2022.12.001","article-title":"Targeting\nlactate metabolism for cancer immunotherapy - a matter of precision","volume":"88","author":"Heuser","year":"2023","journal-title":"Seminars in cancer biology"},{"issue":"1","key":"2026072521082602900_cit8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint\ninhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"2026072521082602900_cit9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121257","article-title":"Nanoparticle\ndelivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control\nwith less systemic adverse effects in cancer immunotherapy","volume":"280","author":"Kim","year":"2022","journal-title":"Biomaterials"},{"issue":"3","key":"2026072521082602900_cit10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.apsb.2021.08.020","article-title":"Emerging role of natural\nproducts in cancer immunotherapy","volume":"12","author":"Dong","year":"2022","journal-title":"Acta pharmaceutica\nSinica. B"},{"issue":"2","key":"2026072521082602900_cit11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3322\/caac.21818","article-title":"Immunosurveillance\nin clinical cancer management","volume":"74","author":"Kroemer","year":"2024","journal-title":"CA: a cancer\njournal for clinicians"},{"issue":"22","key":"2026072521082602900_cit12","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202309994","article-title":"Chimeric Peptide-Engineered\nSelf-Delivery Nanomedicine for Photodynamic-Triggered Breast Cancer\nImmunotherapy by Macrophage Polarization","volume":"20","author":"Liu","year":"2024","journal-title":"Small"},{"issue":"26","key":"2026072521082602900_cit13","doi-asserted-by":"publisher","first-page":"33169","DOI":"10.1021\/acsami.4c06149","article-title":"Self-Delivery Nanobooster\nto Enhance Immunogenic Cell Death for Cancer Chemoimmunotherapy","volume":"16","author":"Yan","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"2","key":"2026072521082602900_cit14","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1021\/acsami.4c13433","article-title":"Mitochondria-Targeted\nIcaritin Nanoparticles Induce Immunogenic Cell Death in Hepatocellular\nCarcinoma","volume":"17","author":"Chen","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2026072521082602900_cit15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bioactmat.2022.08.028","article-title":"A tumor cell\nmembrane-coated self-amplified nanosystem as a nanovaccine to boost\nthe therapeutic effect of anti-PD-L1 antibody","volume":"21","author":"Li","year":"2023","journal-title":"Bioactive materials"},{"issue":"6","key":"2026072521082602900_cit16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting\nimmunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nature reviews. Drug discovery"},{"key":"2026072521082602900_cit17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1201404","article-title":"Hepatotoxic\nmechanism of cantharidin:\ninsights and strategies for therapeutic intervention","volume":"14","author":"Jin","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"2","key":"2026072521082602900_cit18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3390\/ijms24021179","article-title":"Cantharidin and Its\nAnalogue Norcantharidin Inhibit Metastasis-Inducing Genes S100A4 and\nMACC1","volume":"24","author":"Scho\u0308pe","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"2026072521082602900_cit19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ijc.11405","article-title":"Analysis of gene expression profiles in human HL-60\ncell exposed to cantharidin using cDNA microarray","volume":"108","author":"Zhang","year":"2004","journal-title":"International journal of cancer"},{"issue":"11","key":"2026072521082602900_cit20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41389-018-0102-2","article-title":"The combination\nof cantharidin and antiangiogenic therapeutics presents additive antitumor\neffects against pancreatic cancer","volume":"7","author":"Xu","year":"2018","journal-title":"Oncogenesis"},{"issue":"11","key":"2026072521082602900_cit21","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1158\/1535-7163.MCT-06-0273","article-title":"Cantharidin-induced\nmitotic arrest\nis associated with the formation of aberrant mitotic spindles and\nlagging chromosomes resulting, in part, from the suppression of PP2Aalpha","volume":"5","author":"Bonness","year":"2006","journal-title":"Molecular cancer therapeutics"},{"issue":"35","key":"2026072521082602900_cit22","doi-asserted-by":"publisher","first-page":"19355","DOI":"10.1002\/anie.202106392","article-title":"Charge-Reversal\nPolymer Nano-modulators for Photodynamic Immunotherapy\nof Cancer","volume":"60","author":"He","year":"2021","journal-title":"Angewandte Chemie (International\ned. in English)"},{"issue":"6","key":"2026072521082602900_cit23","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.xphs.2020.03.001","article-title":"18-GA-Suc\nModified Liposome Loading Cantharidin for Augmenting Hepatic Specificity:\nPreparation, Characterization, Antitumor Effects, and Liver-Targeting\nEfficiency","volume":"109","author":"Zhu","year":"2020","journal-title":"Journal of pharmaceutical sciences"},{"issue":"6","key":"2026072521082602900_cit24","doi-asserted-by":"publisher","DOI":"10.5070\/D3206022861","article-title":"Cantharidin: a comprehensive\nreview of the clinical literature","volume":"20","author":"Torbeck","year":"2014","journal-title":"Dermatol.\nOnline J."},{"issue":"1","key":"2026072521082602900_cit25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","article-title":"Smart nanoparticles\nfor cancer therapy","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target.\nTher."},{"key":"2026072521082602900_cit26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.addr.2020.09.009","article-title":"Polymeric\nmicelles for the delivery\nof poorly soluble drugs: From nanoformulation to clinical approval","volume":"156","author":"Hwang","year":"2020","journal-title":"Advanced drug delivery reviews"},{"issue":"1","key":"2026072521082602900_cit27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-020-01297-0","article-title":"Two nanoformulations\ninduce reactive oxygen species and immunogenetic cell death for synergistic\nchemo-immunotherapy eradicating colorectal cancer and hepatocellular\ncarcinoma","volume":"20","author":"Guo","year":"2021","journal-title":"Mol. Cancer"},{"key":"2026072521082602900_cit28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2024.213824","article-title":"Naturally\nsourced amphiphilic peptides as paclitaxel vehicles for breast cancer\ntreatment","volume":"159","author":"Chen","year":"2024","journal-title":"Biomaterials advances"},{"issue":"10294","key":"2026072521082602900_cit29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab\nplus chemotherapy versus chemotherapy alone for advanced gastric,\ngastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate\n649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"11","key":"2026072521082602900_cit30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint\ninhibitor use in patients with cancer and pre-existing autoimmune\ndiseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nature reviews. Rheumatology"},{"issue":"15","key":"2026072521082602900_cit31","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy\nin Non-Small Cell Lung Cancer: Facts and Hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clinical cancer research: an official journal of the American Association\nfor Cancer Research"},{"issue":"10","key":"2026072521082602900_cit32","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-Year Survival and\nCorrelates Among Patients With Advanced Melanoma, Renal Cell Carcinoma,\nor Non-Small Cell Lung Cancer Treated With Nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA oncology"},{"issue":"28","key":"2026072521082602900_cit33","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-Year\nOverall Survival\nfor Patients With Advanced Non\u2013Small-Cell Lung Cancer Treated\nWith Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","volume":"37","author":"Garon","year":"2019","journal-title":"Journal of clinical oncology: official journal of the American\nSociety of Clinical Oncology"},{"issue":"8004","key":"2026072521082602900_cit34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT\nantibody improves PD-L1 blockade through myeloid and T(reg)\ncells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"},{"key":"2026072521082602900_cit35","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216239","article-title":"Tackling the current dilemma of immunotherapy\nin extensive-stage small cell lung cancer: A promising strategy of\ncombining with radiotherapy","volume":"565","author":"Kang","year":"2023","journal-title":"Cancer letters"},{"issue":"2","key":"2026072521082602900_cit36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003427","article-title":"Evaluating the efficacy\nof a priming dose of cyclophosphamide prior to pembrolizumab to treat\nmetastatic triple negative breast cancer","volume":"10","author":"Anders","year":"2022","journal-title":"J.\nImmunother. Cancer"},{"issue":"10278","key":"2026072521082602900_cit37","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour\nefficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"Lancet\n(London, England)"},{"issue":"21","key":"2026072521082602900_cit38","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1158\/1078-0432.CCR-19-0475","article-title":"Genetic\nAberrations in the CDK4 Pathway Are Associated with Innate Resistance\nto PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma","volume":"25","author":"Yu","year":"2019","journal-title":"Clinical cancer research: an official journal of the American\nAssociation for Cancer Research"},{"issue":"4","key":"2026072521082602900_cit39","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming Resistance\nto Tumor-Targeted and Immune-Targeted\nTherapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer discovery"},{"issue":"3","key":"2026072521082602900_cit40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-013-1508-5","article-title":"Frequencies of circulating MDSC correlate\nwith clinical outcome of melanoma patients treated with ipilimumab","volume":"63","author":"Meyer","year":"2014","journal-title":"Cancer immunology, immunotherapy: CII"},{"issue":"3","key":"2026072521082602900_cit41","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/cancers6031670","article-title":"Tumor-associated macrophages\nas major players in the tumor microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers"},{"issue":"3","key":"2026072521082602900_cit42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/vaccines4030028","article-title":"Regulatory T Cells in the Tumor Microenvironment and\nCancer Progression: Role and Therapeutic Targeting","volume":"4","author":"Chaudhary","year":"2016","journal-title":"Vaccines"},{"issue":"1","key":"2026072521082602900_cit43","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.apsb.2021.06.005","article-title":"A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside\nRg3 and quercetin for chemo-immunotherapy in colorectal cancer","volume":"12","author":"Sun","year":"2022","journal-title":"Acta pharmaceutica Sinica. B"},{"key":"2026072521082602900_cit44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122278","article-title":"Focused acoustic vortex-mediated\nsonochemotherapy for the amplification\nof immunogenic cell death combined with checkpoint blockade to potentiate\ncancer immunotherapy","volume":"301","author":"Ya","year":"2023","journal-title":"Biomaterials"},{"key":"2026072521082602900_cit45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121407","article-title":"Enhancement\nof anti-PD-1\/PD-L1 immunotherapy for osteosarcoma\nusing an intelligent autophagy-controlling metal organic framework","volume":"282","author":"Ge","year":"2022","journal-title":"Biomaterials"},{"issue":"3","key":"2026072521082602900_cit46","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1021\/acsnano.1c09048","article-title":"Nitric Oxide Induces\nImmunogenic Cell Death and Potentiates Cancer Immunotherapy","volume":"16","author":"Jiang","year":"2022","journal-title":"ACS Nano"},{"issue":"2","key":"2026072521082602900_cit47","doi-asserted-by":"publisher","first-page":"464","DOI":"10.7150\/thno.22711","article-title":"Recent Advances in the Application\nof Vitamin E TPGS for Drug Delivery","volume":"8","author":"Yang","year":"2018","journal-title":"Theranostics"},{"issue":"32","key":"2026072521082602900_cit48","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302705","article-title":"NAT10\/ac4C\/FOXP1 Promotes\nMalignant Progression and Facilitates Immunosuppression\nby Reprogramming Glycolytic Metabolism in Cervical Cancer","volume":"10","author":"Chen","year":"2023","journal-title":"Adv. Sci."},{"issue":"1","key":"2026072521082602900_cit49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-022-00356-0","article-title":"New insights\ninto epigenetic regulation of resistance to PD-1\/PD-L1 blockade cancer\nimmunotherapy: mechanisms and therapeutic opportunities","volume":"11","author":"Dai","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"5","key":"2026072521082602900_cit50","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41577-019-0140-9","article-title":"Metabolic interventions\nin the immune response to cancer","volume":"19","author":"O\u2019Sullivan","year":"2019","journal-title":"Nature reviews.\nImmunology"},{"key":"2026072521082602900_cit51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110755","article-title":"Norcantharidin:\nresearch advances in pharmaceutical\nactivities and derivatives in recent years","volume":"131","author":"Zhou","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"2026072521082602900_cit52","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104868","article-title":"Cantharidin treatment\ninhibits hepatocellular carcinoma development\nby regulating the JAK2\/STAT3 and PI3K\/Akt pathways in an EphB4-dependent\nmanner","volume":"158","author":"Zhu","year":"2020","journal-title":"Pharmacological research"}],"container-title":["ACS Applied Materials &amp; Interfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsami.5c05498","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aamick\/article-pdf\/17\/29\/41571\/66266574\/acsami.5c05498.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aamick\/article-pdf\/17\/29\/41571\/66266574\/acsami.5c05498.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:42:20Z","timestamp":1785073340000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aamick\/article\/17\/29\/41571\/3638514\/Cantharidin-Loaded-Nanomedicine-Modified-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":52,"journal-issue":{"issue":"29","published-online":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2025,7,23]]}},"URL":"https:\/\/doi.org\/10.1021\/acsami.5c05498","relation":{},"ISSN":["1944-8244","1944-8252"],"issn-type":[{"value":"1944-8244","type":"print"},{"value":"1944-8252","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}